Learning Objectives
Upon completion of this activity, participants should be able to:
Compare and contrast the benefits and disadvantages of neoadjuvant treatment approaches for a variety of GI malignancies.
Discuss the integration of targeted therapies in the treatment of GI malignancies.
Review the latest diagnostic and prognostic tools for managing GI malignancies.
Earn CME credit by reading summaries and expert commentary on the management of patients with gastrointestinal cancers.
Topics covered include:
-
Cisplatin- vs Irinotecan-Containing Combination Regimens in the Treatment of Gastric Cancer
-
Oxaliplatin Plus Infusional 5-Fluorouracil/Leucovorin or Capecitabine as First-line Treatment for Advanced Colorectal Carcinoma
-
Bortezomib-Containing Regimens for Gastric and Gastroesophageal Cancers
-
Treatment of Advanced Pancreatic Cancer With Erlotinib and Gemcitabine
-
Cetuximab/Bevacizumab for Irinotecan-refractory Colorectal Cancer
-
Prognostic Role of CA19-9 in Patients With Pancreatic Cancer
-
HER Dimerization and Prognosis in Metastatic Colorectal Cancer
-
Novel Targets for Chemoprevention of Gastric Cancer